Oxymetazoline
MedicationAfrin, Dristan, Nostrilla, Rhofade, Vicks
Topical decongestant
Research strength: 3 / 5
MotherToBaby reports that studies at recommended doses do not suggest a higher chance of birth defects, but it does not give a first-trimester estimate. In Yau et al.'s 2013 case-control study, first-trimester use of intranasal decongestants overall and imidazoline drugs as a group was associated with pyloric stenosis; the estimate for oxymetazoline alone was imprecise (OR 1.8, 95% CI 0.7 to 4.8). The NHS page, last reviewed in 2022, says pregnancy evidence for decongestants is unclear and they should be used only when directed by a healthcare professional; a 2026 respiratory review advises minimizing topical use and says the balance may favor avoiding it. Yau et al. describe these comparisons as exploratory and caution that multiple comparisons may have produced chance findings. Ask your provider about your situation.
Last reviewed: 2026-10-16
Research strength: 3 / 5
MotherToBaby reports no studies have assessed pregnancy problems such as miscarriage, preterm delivery, or low birth weight, and it does not separate birth-defect results by trimester. Yau et al.'s case-control study reported a second-trimester association between oxymetazoline and renal collecting-system anomalies (OR 3.1, 95% CI 1.3 to 6.9). The NHS page, last reviewed in 2022, says pregnancy evidence for decongestants is unclear and they should be used only when directed by a healthcare professional; a 2026 respiratory review advises minimizing topical use and says the balance may favor avoiding it. Yau et al. describe the result as exploratory and say the association warrants further exploration. Ask your provider about your situation.
Last reviewed: 2026-10-16
Research strength: 3 / 5
MotherToBaby does not give a third-trimester-specific birth-defect estimate and reports no studies on preterm birth, low birth weight, or later child learning and behavior. Rayburn et al.'s third-trimester study included 12 healthy pregnancies at 27 to 39 weeks; after one nasal dose, it found no significant change in measured maternal or fetal blood-flow readings over two hours. The NHS page, last reviewed in 2022, says pregnancy evidence for decongestants is unclear and they should be used only when directed by a healthcare professional; a 2026 respiratory review advises minimizing topical use and says the balance may favor avoiding it. The Rayburn study examined short-term blood-flow measures only, not pregnancy outcomes or repeated use. Ask your provider about your situation.
Last reviewed: 2026-10-16
Sources
Oxymetazoline — Breastfeeding
Research strength: 1 / 5
MotherToBaby reports that oxymetazoline has not been studied during breastfeeding and that little is expected to enter the mother's blood or milk when used as directed. LactMed likewise says no information is available on use specifically during breastfeeding and expects very little to reach the infant because of local use and limited absorption. LactMed prefers it over oral systemic decongestants and says topical use on the face is unlikely to present a risk to a nursing infant. A 2026 respiratory review offers a more cautious view, saying the balance of risks and benefits favors avoiding topical oxymetazoline during lactation. This difference reflects the lack of direct milk-level or infant-outcome data. Ask your provider about your situation.
Last reviewed: 2026-10-16
Pregnancy
MotherToBaby reports that studies at recommended doses do not suggest a higher chance of birth defects, but its fact sheet does not give trimester-specific estimates. The sheet reports no studies assessing miscarriage, preterm delivery, low birth weight, or later learning and behavior. Yau et al. studied 12,734 infants with malformations and 7,606 nonmalformed controls in a case-control study using 1993 to 2010 data. In exploratory first-trimester comparisons, the study reported pyloric stenosis associations for intranasal decongestants overall (OR 1.9, 95% CI 1.0 to 3.5) and imidazoline derivatives as a group (OR 2.2, 95% CI 1.1 to 4.5). Among 82 first-trimester oxymetazoline-only users, five had pyloric stenosis (OR 1.8, 95% CI 0.7 to 4.8); three oxymetazoline-only cases had tracheo-esophageal fistula, too few for an estimate. In the imidazoline group, the study reported an association with tracheo-esophageal fistula (OR 3.3, 95% CI 1.2 to 8.9). For second-trimester oxymetazoline, it reported an association with renal collecting-system anomalies (OR 3.1, 95% CI 1.3 to 6.9); the available article text does not give the exposed-count denominator for this estimate. The authors call the intranasal comparisons exploratory, note multiple comparisons and no prior hypotheses, and say the findings warrant cautious interpretation and further study. Rayburn et al. monitored 12 healthy pregnancies at 27 to 39 weeks after a single nasal dose and found no significant acute change in maternal blood pressure or pulse, uterine artery, fetal aorta, or umbilical artery flow measures over two hours. That small physiologic study does not address birth outcomes or repeated use. No absolute risk estimate for oxymetazoline was identified in these studies.
Breastfeeding
MotherToBaby and LactMed report no specific published human information on oxymetazoline levels in breast milk or effects in breastfed infants. MotherToBaby says very little is thought to be absorbed into the body or breast milk when used as directed in the nose, eyes, or on the skin. LactMed estimates very little should reach the infant because administration is local and maternal absorption is limited, and it recommends oxymetazoline over oral systemic decongestants such as pseudoephedrine. These are route-based exposure estimates, not conclusions from direct infant-outcome studies.
Oxymetazoline is an alpha-adrenergic medicine used in nasal sprays and drops, eye drops, and topical skin preparations. The current Afrin Original label reviewed is a 0.05% nasal spray. The live brand list includes Afrin, Dristan, Nostrilla, Rhofade, and Vicks; these brand names can refer to different forms and label directions.
What was tested
The largest retrieved pregnancy study was a case-control analysis of 20,340 participants overall, including 12,734 malformed cases and 7,606 nonmalformed controls; oxymetazoline exposure groups were much smaller. The 2013 paper's full text was read. Rayburn 1990 was a single-dose Doppler study of 12 healthy third-trimester pregnancies with two hours of follow-up, not a study of pregnancy outcomes. No prospective trial of repeated oxymetazoline use in pregnancy or a human milk-level study was identified. The 2026 respiratory review provides secondary advice, not new oxymetazoline-specific primary outcome data.
How should limited pregnancy evidence affect interpretation of oxymetazoline use?
- Source A says
- The NHS page says pregnancy evidence for decongestants is unclear and that they should be used only if directed by a healthcare professional. A 2026 respiratory review says to minimize topical oxymetazoline and that the pregnancy risk-benefit balance favors avoiding it. (NHS: Decongestants, Gleeson et al., 2026 review: Asthma management in pregnancy and lactation)
- Source B says
- MotherToBaby reports that studies at recommended doses do not suggest a higher chance of birth defects. Yau et al. found exploratory first-trimester and second-trimester associations, but state that the intranasal findings need cautious interpretation and further study. (MotherToBaby: Oxymetazoline fact sheet, Yau et al., American Journal of Epidemiology 2013: Decongestants during pregnancy and birth defects)
- Why they differ
- The NHS page gives general advice for decongestants and was last reviewed in 2022. The 2026 review makes a cautious recommendation in a table for allergic-rhinitis medicines, but it is not a new oxymetazoline-specific human outcome study. MotherToBaby gives a drug-specific summary but does not discuss the detailed Yau associations. Yau reports exploratory associations from multiple comparisons with small drug-specific groups.
- What the evidence shows overall
- No study establishes that oxymetazoline caused the observed birth-defect associations. The available human evidence is limited, and the NHS precaution and the newer review's cautious position differ from MotherToBaby's broad summary of birth-defect findings.
Should oxymetazoline be considered compatible during breastfeeding when direct infant data are absent?
- Source A says
- Gleeson et al.'s 2026 respiratory review says the risk-benefit balance favors avoiding topical oxymetazoline during lactation. (Gleeson et al., 2026 review: Asthma management in pregnancy and lactation)
- Source B says
- LactMed expects very little to reach the infant because use is local and maternal absorption is limited, recommends it over oral systemic decongestants, and says topical facial use is unlikely to present a risk. MotherToBaby also expects little to enter milk when used as directed. (LactMed (NIH/NLM): Oxymetazoline, MotherToBaby: Oxymetazoline fact sheet)
- Why they differ
- Direct human milk-level and infant-outcome information was not found. The 2026 review presents a more precautionary risk-benefit judgment, while LactMed and MotherToBaby base their assessment on local administration and expected low maternal absorption.
- What the evidence shows overall
- The published sources disagree on whether route-based low-exposure estimates justify use during lactation. None of these sources provides a direct oxymetazoline milk-level or infant-outcome estimate.
How long should nasal oxymetazoline be used?
- Source A says
- The current U.S. Afrin Original label says not to use the product for more than 3 days and warns that frequent or prolonged use may cause congestion to recur or worsen. (DailyMed: Afrin Original nasal spray label (JC World Bell repackaged label))
- Source B says
- The UK MHRA's April 2026 update says nasal oxymetazoline products should not be used for more than 5 consecutive days. It also reports rebound congestion, rhinitis medicamentosa, tachyphylaxis, and contraindicates use with other oral or nasal sympathomimetic decongestants. (UK MHRA Drug Safety Update: Nasal decongestant sprays and drops containing oxymetazoline/xylometazoline)
- Why they differ
- The U.S. product label and UK regulator update apply in different markets and refer to different product information. Both warn about rebound or worsening congestion with prolonged use, but their stated maximum durations differ.
- What the evidence shows overall
- The U.S. label's 3-day limit is stricter than the MHRA's 5-day limit. The limits are presented with their product and country scope rather than combined into one duration.
- The NHS says that pregnancy evidence for decongestants is unclear and that they should only be used if a healthcare professional directs their use. (NHS: Decongestants)
- The U.S. Afrin Original label says not to use the nasal spray for more than 3 days; frequent or prolonged use may cause congestion to recur or worsen. (DailyMed: Afrin Original nasal spray label)
- The MHRA's April 2026 update sets a 5-consecutive-day maximum for UK oxymetazoline sprays and contraindicates concurrent use with other oral or nasal sympathomimetic decongestants. (UK MHRA Drug Safety Update, 30 April 2026)
- LactMed recommends oxymetazoline over oral systemic decongestants during breastfeeding. (LactMed (NIH/NLM): Oxymetazoline)
General research, not specific to pregnancy.
The U.S. Afrin Original label limits use to 3 days, while the April 2026 MHRA update sets a 5-day maximum for UK products. Both describe rebound or worsening congestion with overuse, and the MHRA also reports longer-lasting nasal changes and reduced effect after repeated use. The MHRA update contraindicates concurrent use with other oral or nasal sympathomimetic decongestants.
- The Afrin Original label says not to use for more than 3 days and warns that frequent or prolonged use may cause nasal congestion to recur or worsen. (DailyMed: Afrin Original nasal spray label (JC World Bell repackaged label))
- The Afrin Original label says people who are pregnant or breastfeeding should ask a health professional before use. (DailyMed: Afrin Original nasal spray label (JC World Bell repackaged label))
- The MHRA reports rebound congestion, rhinitis medicamentosa, and tachyphylaxis with overuse and states that UK products should not be used for more than 5 consecutive days. (UK MHRA Drug Safety Update: Nasal decongestant sprays and drops containing oxymetazoline/xylometazoline)
- The MHRA says nasal oxymetazoline is contraindicated for people taking other oral or nasal sympathomimetic decongestants. (UK MHRA Drug Safety Update: Nasal decongestant sprays and drops containing oxymetazoline/xylometazoline)
- MotherToBaby: Oxymetazoline fact sheetTeratology serviceSecondary
- LactMed (NIH/NLM): OxymetazolineUS governmentSecondaryPage dated 2025-02-15Independent check
- Yau et al., American Journal of Epidemiology 2013: Decongestants during pregnancy and birth defectsUS governmentPrimaryIndependent check
- Rayburn et al., Obstetrics and Gynecology 1990: Single-dose intranasal decongestant and uterine/fetal blood flowUS governmentPrimaryIndependent check
- NHS: DecongestantsUK governmentSecondaryPage dated 2022-11-03Independent check
- Gleeson et al., 2026 review: Asthma management in pregnancy and lactationUS governmentPrimaryPage dated 2026-04-10
- DailyMed: Afrin Original nasal spray label (JC World Bell repackaged label)Drug company labelTertiaryPage dated 2026-08-31
- UK MHRA Drug Safety Update: Nasal decongestant sprays and drops containing oxymetazoline/xylometazolineUK governmentSecondaryPage dated 2026-04-30Independent check
Last reviewed 2026-10-16
Independent check 2026-10-16
Not yet clinician-reviewed
Ask your provider about your situation.